Kinrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) is a noninfectious, sterile vaccine for intramuscular administration.
Kinrix includes D-antigen Units (DU) of Type 1 poliovirus (Mahoney), 8 DU of Type 2 poliovirus (MEF-1), and 32 DU of Type 3 poliovirus (Saukett).
The inactivated poliovirus component of Kinrix is an enhanced potency component. Each of the 3 strains of poliovirus is individually grown in VERO cells, a continuous line of monkey kidney cells, cultivated on microcarriers.
The 3 purified viral strains are pooled to form a trivalent concentrate.
The diphtheria, tetanus, and pertussis components of KINRIX are the same as those in INFANRIX and PEDIARIX and the poliovirus component is the same as that in PEDIARIX
A single dose of Kinrix is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose.
Kinrix is administered as a single intramuscular injection. The preferred site of administration is the deltoid muscle of the upper arm.
March 31, 2021 - Combination Vaccine Market May See a Big Move.
August 5, 2020 - DTAP VACCINE MARKET IS ESTIMATED TO GROW AT THE HIGHEST GROWTH RATE TILL 2027 | GLAXOSMITHKLINE, SANOFI PASTEUR, PROTEIN SCIENCES CORPORATION, NOVARTIS AG